| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $38,724,197 | 3 | 20 |
Sells | $22,365,483 | 12 | 80 |
| EcoR1 Capital, LLC | 10 percent owner | 2 | $38.69M | 0 | $0 | $38.69M |
| Gall Matthew | Chief Financial Officer | 1 | $38,635 | 0 | $0 | $38,635 |
| Hallal David | director | 0 | $0 | 3 | $1.16M | $-1.16M |
| Detheux Michel | Chief Executive Officer | 0 | $0 | 6 | $2.73M | $-2.73M |
| MPM BioVentures 2014, L.P. | Former 10% Owner | 0 | $0 | 1 | $5.08M | $-5.08M |
| MPM BIOVENTURES 2018, L.P. | Former 10% Owner | 0 | $0 | 1 | $5.08M | $-5.08M |
| GADICKE ANSBERT | Former 10% Owner | 0 | $0 | 1 | $8.32M | $-8.32M |
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Over the last 12 months, insiders at iTeos Therapeutics, Inc. have bought $38.72M and sold $22.37M worth of iTeos Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at iTeos Therapeutics, Inc. have bought $49.05M and sold $53.25M worth of stock each year.
Highest buying activity among insiders over the last 12 months: EcoR1 Capital, LLC (10 percent owner) — $38.69M. Gall Matthew (Chief Financial Officer) — $38,635.
The last purchase of 3,300,000 shares for transaction amount of $26.4M was made by EcoR1 Capital, LLC (10 percent owner) on 2025‑05‑15.
| 2025-06-10 | Sale | Detheux Michel | Chief Executive Officer | 52,283 0.1365% | $10.02 | $523,876 | +0.69% | |
| 2025-06-09 | Sale | Detheux Michel | Chief Executive Officer | 8,400 0.0219% | $10.03 | $84,252 | +0.59% | |
| 2025-06-09 | Sale | Detheux Michel | Chief Executive Officer | 52,282 0.1365% | $10.03 | $524,388 | +0.59% | |
| 2025-06-06 | Sale | Hallal David | director | 38,228 0.1006% | $10.24 | $391,455 | -0.74% | |
| 2025-06-06 | Sale | Detheux Michel | Chief Executive Officer | 52,282 0.1371% | $10.21 | $533,799 | -0.74% | |
| 2025-06-05 | Sale | Hallal David | director | 38,227 0.0996% | $10.15 | $388,004 | -0.79% | |
| 2025-06-05 | Sale | Detheux Michel | Chief Executive Officer | 52,282 0.1362% | $10.15 | $530,662 | -0.79% | |
| 2025-06-04 | Sale | Hallal David | director | 38,227 0.0986% | $10.07 | $384,946 | -0.98% | |
| 2025-06-04 | Sale | Detheux Michel | Chief Executive Officer | 52,283 0.1353% | $10.10 | $528,058 | -0.98% | |
| 2025-05-15 | EcoR1 Capital, LLC | 10 percent owner | 3.3M 8.6545% | $8.00 | $26.4M | +25.97% | ||
| 2025-05-14 | EcoR1 Capital, LLC | 10 percent owner | 1.66M 4.2236% | $7.41 | $12.29M | +32.04% | ||
| 2025-05-13 | Sale | GADICKE ANSBERT | Former 10% Owner | 1.03M 2.7683% | $8.06 | $8.32M | +27.77% | |
| 2025-05-13 | Sale | MPM BIOVENTURES 2018, L.P. | Former 10% Owner | 630,191 1.6906% | $8.06 | $5.08M | +27.77% | |
| 2025-05-13 | Sale | MPM BioVentures 2014, L.P. | Former 10% Owner | 630,191 1.6906% | $8.06 | $5.08M | +27.77% | |
| 2024-11-19 | Gall Matthew | Chief Financial Officer | 5,000 0.0135% | $7.73 | $38,635 | -3.04% | ||
| 2023-10-12 | Gall Matthew | Chief Financial Officer | 5,000 0.0136% | $8.37 | $41,850 | +30.92% | ||
| 2023-08-23 | Sale | Boxer Capital, LLC | 350,000 1.1785% | $16.26 | $5.69M | -16.00% | ||
| 2022-06-08 | Sale | Hallal David | 1,171 0.0033% | $19.51 | $22,846 | -3.14% | ||
| 2022-05-09 | Sale | Davis Aaron I. | 337,109 0.7412% | $18.25 | $6.15M | -17.43% | ||
| 2022-04-28 | Sale | Davis Aaron I. | 115,000 0.3152% | $27.01 | $3.11M | -29.86% |
| EcoR1 Capital, LLC | 10 percent owner | 10688978 27.9277% | $109.88M | 2 | 0 | |
| GADICKE ANSBERT | Former 10% Owner | 3452797 9.0213% | $35.49M | 1 | 44 | +45.66% |
| MPM BioVentures 2014, L.P. | Former 10% Owner | 2108594 5.5092% | $21.68M | 1 | 44 | +45.66% |
| MPM BIOVENTURES 2018, L.P. | Former 10% Owner | 2108594 5.5092% | $21.68M | 0 | 44 | |
| Gall Matthew | Chief Financial Officer | 65429 0.1709% | $672,610.12 | 3 | 1 | +20.36% |
| Hallal David | director | 0 0% | $0 | 0 | 5 | |
| Detheux Michel | Chief Executive Officer | 0 0% | $0 | 0 | 31 | |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 4417259 11.5412% | $45.41M | 1 | 0 | +45.66% |
| LEWIS JOSEPH | 3142058 8.2094% | $32.3M | 0 | 1 | ||
| Davis Aaron I. | 2154058 5.628% | $22.14M | 2 | 2 | +3.01% | |
| Boxer Capital, LLC | 1804058 4.7136% | $18.55M | 1 | 3 | +45.66% | |
| McGrath Yvonne | Chief Scientific Officer | 0 0% | $0 | 0 | 6 | |
| Lager Joanne Jenkins | Chief Medical Officer | 0 0% | $0 | 0 | 7 | |
| Biniszkiewicz Detlev | director | 0 0% | $0 | 0 | 1 |
$14,527,743 | 76 | 38.40% | $399.25M | |
$41,446,394 | 27 | 12.91% | $432.83M | |
$27,105,902 | 21 | -16.06% | $407.93M | |
$47,220,584 | 21 | -23.04% | $370.73M | |
$3,556,951 | 18 | 9.64% | $377.32M | |
$14,865,077 | 18 | -28.56% | $365.27M | |
$3,287,638 | 15 | -0.23% | $372.5M | |
$70,704,995 | 14 | 67.19% | $384.83M | |
$65,355,913 | 13 | -3.42% | $430.93M | |
$2,788,839 | 12 | 6.73% | $417.63M | |
$81,667,942 | 12 | -57.54% | $349.51M | |
$19,659,196 | 11 | 21.81% | $425.36M | |
iTeos Therapeutics, Inc. (ITOS) | $157,484,277 | 8 | 28.67% | $393.45M |
$335,001 | 6 | -23.71% | $363.06M | |
$15,652,720 | 6 | -4.77% | $376.53M | |
$51,588,185 | 5 | 19.18% | $357.23M | |
$79,246,559 | 5 | -27.73% | $432.54M | |
$504,640 | 1 | 16.84% | $443.45M | |
$3,850,000 | 1 | -51.32% | $428.3M |
| Increased Positions | 61 | +36.53% | 8M | +21.09% |
| Decreased Positions | 71 | -42.51% | 5M | -13.74% |
| New Positions | 20 | New | 790,306 | New |
| Sold Out Positions | 25 | Sold Out | 2M | Sold Out |
| Total Postitions | 157 | -5.99% | 40M | +7.35% |
| Blackrock, Inc. | $35,037.00 | 11.87% | 4.51M | +707,738 | +18.62% | 2025-03-31 |
| Boxer Capital, Llc | $22,898.00 | 7.76% | 2.95M | 0 | 0% | 2024-09-30 |
| Mpm Asset Management Llc | $21,280.00 | 7.21% | 2.74M | 0 | 0% | 2024-12-31 |
| Bvf Inc/Il | $18,065.00 | 6.12% | 2.33M | +2M | New | 2024-12-31 |
| Ra Capital Management, L.P. | $16,257.00 | 5.51% | 2.09M | -1M | -34.3% | 2024-12-31 |
| Jpmorgan Chase & Co | $16,075.00 | 5.44% | 2.07M | +2M | +342.69% | 2024-12-31 |
| Mpm Bioimpact Llc | $13,566.00 | 4.6% | 1.75M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $12,696.00 | 4.3% | 1.63M | -22,781 | -1.38% | 2024-12-31 |
| Citadel Advisors Llc | $11,129.00 | 3.77% | 1.43M | +196,003 | +15.86% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $9,402.00 | 3.18% | 1.21M | +163,880 | +15.66% | 2024-12-31 |